{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:54:33Z","timestamp":1772643273846,"version":"3.50.1"},"reference-count":9,"publisher":"S. Karger AG","issue":"2","license":[{"start":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T00:00:00Z","timestamp":1528156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T00:00:00Z","timestamp":1528156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Case Rep Dermatol"],"abstract":"<jats:p>Checkpoint inhibitors are novel and promising treatment options for different types of cancer. Programmed cell death 1 (PD-1) inhibitors, such as pembrolizumab, have been shown to significantly raise the survival rates of disseminated malignant melanoma (MM). Autoimmune adverse reactions are very common in checkpoint inhibitors. We present 2 cases of bullous pemphigoid, as adverse reactions to pembrolizumab-treated MM.<\/jats:p>","DOI":"10.1159\/000489661","type":"journal-article","created":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T21:01:51Z","timestamp":1528232511000},"page":"154-157","source":"Crossref","is-referenced-by-count":20,"title":["Bullous Pemphigoid as an Adverse Reaction to Pembrolizumab: Two Case Reports"],"prefix":"10.1159","volume":"10","author":[{"given":"Kenneth","family":"Thomsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon","family":"Diernaes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trine\u00a0Heide","family":"\u00d8llegaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Spaun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6485-3158","authenticated-orcid":false,"given":"Christian","family":"Vestergaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2018,6,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2013.12.001"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61140-4"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12366"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxm057"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200694"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.1021774"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000155"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000260"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13042"}],"container-title":["Case Reports in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/489661","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/489661","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:31:41Z","timestamp":1745425901000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000489661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,5]]},"references-count":9,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,9,3]]}},"URL":"https:\/\/doi.org\/10.1159\/000489661","archive":["Portico"],"relation":{},"ISSN":["1662-6567"],"issn-type":[{"value":"1662-6567","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,5]]}}}